Gadolinium-DOTA enhanced MR imaging of prostatic lesions. Preliminary results on 14 cases.

Fourteen patients with prostatic carcinoma, benign prostatic hyperplasia, or chronic granulomatous prostatitis underwent gadolinium-DOTA enhanced magnetic resonance imaging of the prostate. Gadolinium-DOTA was administered intravenously in a dosage of 0.1 mmol/kg body weight. All studies were performed on a superconductive 1.5-T system. As compared to noncontrast T1- and T2-weighted images, Gd-DOTA enhanced T1-weighted images were useful in distinguishing malignant tumor from granulomatous prostatitis in one case, but were uncontributive to the differentiation between carcinoma and benign prostatic hyperplasia.